{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:05:47Z","timestamp":1792760747301,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving <jats:bold>[<\/jats:bold><jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the \u201c617 trial\u201d) to evaluate response rate and OS as well as the impact of prior therapies on OS in more than 300 patients treated with <jats:sup>177<\/jats:sup>Lu-PSMA-617.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>The data of 631 metastatic CRPC (mCRPC) patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to <jats:bold>[<\/jats:bold><jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy, and patients for whom a chemotherapy was contraindicated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis included the data of 416 patients, with a median age of 71.9\u00a0years. At the time of analysis, 87 patients (20,9%) were still alive. A total of 53.6% of patients had received both abiraterone and enzalutamide; 75.5% and 26.4% had a history of chemotherapy with docetaxel and cabazitaxel, respectively. A total of 20.4% had had Ra-223. The median OS was 11.1\u00a0months. Prior chemotherapy, the existence of bone and liver metastases, as well as Eastern Cooperative Oncology Group (ECOG) status, were significant prognosticators of worse overall survival in both univariate and multivariate analyses. Patients without any prior chemotherapy showed a significantly longer OS (14.6\u00a0months). The median OS in patients who received one or two lines of chemotherapy with docetaxel or docetaxel followed by cabazitaxel, respectively, was 10.9\u00a0months and 8.9\u00a0months. There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. The other prior therapies did not have any significant impact on OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the present multicenter analysis, chemotherapy-na\u00efve mCRPC patients receiving [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapy had a significantly longer OS than patients with a history of chemotherapy. This remained independent in the multivariate analysis besides presence of bone and liver metastases as negative prognosticators for survival, whereas an ECOG of 0\u20131 is associated with a longer OS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-04797-9","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T01:02:32Z","timestamp":1588899752000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)"],"prefix":"10.1007","volume":"48","author":[{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad R","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Fimmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Rathke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Maffey-Steffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Kabasakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Osvaldo","family":"Garcia-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalevi","family":"Kairemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"4797_CR1","first-page":"555","volume":"28","author":"M Santoni","year":"2014","unstructured":"Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555\u201363.","journal-title":"J Biol Regul Homeost Agents"},{"key":"4797_CR2","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"4797_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","volume":"169","author":"Y Tolkach","year":"2018","unstructured":"Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018;169:447\u201355. https:\/\/doi.org\/10.1007\/s10549-018-4717-y.","journal-title":"Breast Cancer Res Treat"},{"key":"4797_CR4","first-page":"55","volume":"9","author":"K Bouchelouche","year":"2010","unstructured":"Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen-a target for imaging and therapy with radionuclides. Discov Med. 2010;9:55\u201361.","journal-title":"Discov Med"},{"key":"4797_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0820.","journal-title":"Clin Cancer Res"},{"key":"4797_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114. https:\/\/doi.org\/10.1186\/s13550-015-0114-2.","journal-title":"EJNMMI Res"},{"key":"4797_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","volume":"50","author":"H Ahmadzadehfar","year":"2020","unstructured":"Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ. PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med. 2020;50:98\u2013109. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.07.003.","journal-title":"Semin Nucl Med"},{"key":"4797_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/wjnm.WJNM_66_18","volume":"18","author":"RA Aghdam","year":"2019","unstructured":"Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, et al. Efficacy and safety of (177)lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: first experience in west Asia-a prospective study. World J Nucl Med. 2019;18:258\u201365. https:\/\/doi.org\/10.4103\/wjnm.WJNM_66_18.","journal-title":"World J Nucl Med"},{"key":"4797_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"4797_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17:15\u201322. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.014.","journal-title":"Clin Genitourin Cancer"},{"key":"4797_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for Radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.016.","journal-title":"Eur Urol"},{"key":"4797_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","volume":"60","author":"TW Barber","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955\u201362. https:\/\/doi.org\/10.2967\/jnumed.118.216820.","journal-title":"J Nucl Med"},{"key":"4797_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","volume":"44","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448\u201354. https:\/\/doi.org\/10.1007\/s00259-017-3716-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3848-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006\u201313.","journal-title":"J Nucl Med"},{"key":"4797_CR16","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","volume":"57","author":"HR Kulkarni","year":"2016","unstructured":"Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:97S\u2013104S. https:\/\/doi.org\/10.2967\/jnumed.115.170167.","journal-title":"J Nucl Med"},{"key":"4797_CR17","doi-asserted-by":"publisher","first-page":"55567","DOI":"10.18632\/oncotarget.15698","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride. Oncotarget. 2017;8:55567\u201374. https:\/\/doi.org\/10.18632\/oncotarget.15698.","journal-title":"Oncotarget."},{"key":"4797_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00259-017-3877-z","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Bogeman M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243\u20136. https:\/\/doi.org\/10.1007\/s00259-017-3877-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR19","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00259-017-3751-z","volume":"44","author":"A Brauer","year":"2017","unstructured":"Brauer A, Grubert LS, Roll W, Schrader AJ, Schafers M, Bogemann M, et al. (177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663\u201370. https:\/\/doi.org\/10.1007\/s00259-017-3751-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88\u201399. https:\/\/doi.org\/10.1016\/j.eururo.2018.03.028.","journal-title":"Eur Urol"},{"key":"4797_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10967-019-06800-6","volume":"322","author":"N Vahidfar","year":"2019","unstructured":"Vahidfar N, Fallahpoor M, Farzanehfar S, Divband G, Ahmadzadehfar H. Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer. J Radioanal Nucl Chem. 2019;322:237\u201348. https:\/\/doi.org\/10.1007\/s10967-019-06800-6.","journal-title":"J Radioanal Nucl Chem"},{"key":"4797_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","volume":"42","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, et al. [(1)(7)(7)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987\u20138. https:\/\/doi.org\/10.1007\/s00259-014-2978-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.17159\/2078-5151\/2019\/v57n4a3107","volume":"57","author":"M Vorster","year":"2019","unstructured":"Vorster M, Warwick J, Lawal IO, Du Toit P, Vangu M, Nyakale NE, et al. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer. S Afr J Surg. 2019;57:45\u201351.","journal-title":"S Afr J Surg"},{"key":"4797_CR24","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4797_CR25","first-page":"2","volume":"26","author":"H Ahmadzadehfar","year":"2018","unstructured":"Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iranian J Nuclear Med. 2018;26:2\u20138.","journal-title":"Iranian J Nuclear Med"},{"key":"4797_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-0037-1616480","volume":"55","author":"WP Fendler","year":"2016","unstructured":"Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016;55:123\u20138.","journal-title":"Nuklearmedizin."},{"key":"4797_CR27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"key":"4797_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2967\/jnumed.119.234054","volume":"60","author":"K Rahbar","year":"2019","unstructured":"Rahbar K, Bodei L, Morris MJ. Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics. J Nucl Med. 2019;60:1504\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.234054.","journal-title":"J Nucl Med"},{"key":"4797_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1874471011666180629145030","volume":"11","author":"K Kairemo","year":"2018","unstructured":"Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA. Final outcome of 223Ra-therapy and the role of 18F-fluoride-PET in response evaluation in metastatic castration-resistant prostate cancer-a single institution experience. Curr Radiopharm. 2018;11:147\u201352. https:\/\/doi.org\/10.2174\/1874471011666180629145030.","journal-title":"Curr Radiopharm"},{"key":"4797_CR30","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.7150\/thno.35759","volume":"9","author":"K Kessel","year":"2019","unstructured":"Kessel K, Seifert R, Schafers M, Weckesser M, Schlack K, Boegemann M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics. 2019;9:4841\u20138. https:\/\/doi.org\/10.7150\/thno.35759.","journal-title":"Theranostics."},{"issue":"Suppl 1","key":"4797_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.14876","volume":"124","author":"MS Hofman","year":"2019","unstructured":"Hofman MS, Emmett L, Violet J, Zhang AY, Lawrence NJ, Stockler M, et al. TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124(Suppl 1):5\u201313. https:\/\/doi.org\/10.1111\/bju.14876.","journal-title":"BJU Int"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-04797-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T23:33:59Z","timestamp":1620430439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-04797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4797"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04797-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}